{"id":"NCT03110380","sponsor":"Gilead Sciences","briefTitle":"Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Adults Who Are Virologically Suppressed","officialTitle":"A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Switching From a Regimen of Dolutegravir and Either Emtricitabine/Tenofovir Alafenamide or Emtricitabine/Tenofovir Disoproxil Fumarate to a Fixed Dose Combination of Bictegravir/ Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected Subjects Who Are Virologically Suppressed","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-06-12","primaryCompletion":"2018-12-04","completion":"2021-02-10","firstPosted":"2017-04-12","resultsPosted":"2019-11-20","lastUpdate":"2022-01-11"},"enrollment":567,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["HIV-1-infection"],"interventions":[{"type":"DRUG","name":"B/F/TAF","otherNames":["GS-9883/F/TAF","Biktarvy®"]},{"type":"DRUG","name":"F/TAF","otherNames":["Descovy®"]},{"type":"DRUG","name":"DTG","otherNames":["Tivicay®"]},{"type":"DRUG","name":"DTG Placebo","otherNames":[]},{"type":"DRUG","name":"F/TAF Placebo","otherNames":[]},{"type":"DRUG","name":"B/F/TAF Placebo","otherNames":[]}],"arms":[{"label":"B/F/TAF","type":"EXPERIMENTAL"},{"label":"DTG + F/TAF","type":"ACTIVE_COMPARATOR"},{"label":"Open-label Phase B/F/TAF from B/F/TAF","type":"EXPERIMENTAL"},{"label":"Open-label Phase B/F/TAF from DTG + F/TAF","type":"EXPERIMENTAL"}],"summary":"The primary objective of this study is to evaluate the efficacy of switching from a regimen of either dolutegravir (DTG) and emtricitabine /tenofovir alafenamide (F/TAF) or DTG and emtricitabine/tenofovir disoproxil fumarate (F/TDF) to a fixed dose combination (FDC) of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) versus DTG+F/TAF in virologically suppressed HIV-1 infected adults with or without antiretroviral (ARV) resistance.","primaryOutcome":{"measure":"Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm","timeFrame":"Week 48","effectByArm":[{"arm":"B/F/TAF","deltaMin":0.4,"sd":null},{"arm":"DTG + F/TAF","deltaMin":1.1,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":"0.37"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":null},"locations":{"siteCount":94,"countries":["United States","Austria","Canada","France","Germany","Puerto Rico"]},"refs":{"pmids":["32668455","32701823"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":36,"n":284},"commonTop":["Upper respiratory tract infection","Nasopharyngitis","Diarrhoea","Arthralgia","Headache"]}}